Genomic Health (GHDX) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Genomic Health Announces First Quarter 2015 Financial Results and Reports Record Oncotype DX® Test Volume
May 5, 2015 4:01 PM EDTREDWOOD CITY, Calif., May 5, 2015 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2015.
Product revenue was $68.2 million in the first quarter of 2015, compared with $67.0 million for the first quarter of 2014, an increase of 2 percent. On a constant currency basis, product revenue increased 3 percent compared with the prior year.Â
International product revenue was $10.4 million in the first quarter of 2015 and represented 15 percent of product revenue in the quarter.
Reported total product revenue was impacted negatively by $0.8 million... More
